India · Delayed Price · Currency is INR GlaxoSmithKline Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2027
-
Q1 FY 2027 saw 15% sales growth and 24% PAT growth, with innovation assets now 7% of revenue. Strong performance across General Medicines, Vaccines, and Specialty segments, with Shingrix and oncology assets driving momentum. EBITDA and PAT margins expanded, and new launches are expected to sustain double-digit growth.
Fiscal Year 2026
-
Revenue grew 2% for FY 2026, with double-digit EBITDA and PAT growth, driven by strong vaccines and specialty launches. Supply chain issues are resolved, and the innovative portfolio now contributes 6% of sales, with further growth expected from new launches.
-
Quarterly revenue surpassed INR 1,000 crores for the first time, with 8.1% standalone and nearly 10% consolidated growth year-over-year. EBITDA margin improved to 35.9%, driven by strong general medicines, specialty, and vaccine performance, and supply normalization.
-
Q2 sales declined 2.6% to INR 974 crore due to a CMO fire and market softness, but EBITDA margin improved to 34.4%. Vaccines and specialty segments grew strongly, and the oncology business launched in August is expected to drive future growth.
-
Flat revenue in Q1 was offset by strong margin expansion and double-digit PAT and EPS growth, despite supply disruptions and muted demand in acute and derma segments. Oncology launches and vaccine growth are expected to drive a rebound and support double-digit growth ambitions for FY26.
Fiscal Year 2025
-
Revenue grew 9% year-over-year, led by strong volume gains in general medicine and specialty segments, with EBITDA margin rising to 31%. Two oncology launches are planned for FY 2026, and management targets above-market growth while maintaining a robust cash position.
-
Q3 saw 18% revenue growth and 33% EBITDA growth, with all segments posting double-digit gains. Margin improvements, strong cash flow, and new product launches in oncology and adult vaccines underpin a positive outlook, despite industry headwinds and seasonality.
-
Q2 revenue surpassed INR 1,000 crore, up 5% year-over-year, with strong growth in Specialty and Vaccines. EBITDA margin reached 32%, and the NLEM price impact is now fully absorbed. New launches and digital expansion are set to drive future growth.
-
Q1 saw 10% revenue growth, 62% EBITDA growth, and a 9-point margin improvement, driven by strong performance in general medicines, specialty, and vaccines. Digital engagement and new launches supported momentum, with double-digit growth expected to continue.
Fiscal Year 2024
-
Revenue grew 10% with strong specialty and vaccine performance, and EBITDA margin rose to 28%. Digital and omnichannel strategies boosted engagement, while new launches and clinical trials support future growth. Margin improvements and double-digit growth trends are expected to continue.